Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled

Amid growing competition within the CGRP inhibitor class of migraine drugs, Lundbeck’s Vyepti has hit a setback in its market expansion plan.

Vyepti failed to significantly outdo placebo at reducing monthly migraine days in a phase 3 trial called Sunlight, Lundbeck disclosed  Wednesday alongside its second-quarter financial results.